Based on the platform of self-assembling peptides, a technology developed at the Massachusetts Institute of Technology (MIT) in the U.S., our group is expanding its business globally in the areas of surgery, regenerative medicine, and drug delivery systems (DDS).
We contribute to the advancement of medicine through biomaterials.
We are developing a number of applications using self-assembling peptides in three main medical fields.
With a focus on Purestat, which has the strength not only in hemostasis but also in overall strength, we are developing postoperative bleeding materials, mucous membrane lifting-up solutions, vascular embolization materials and so on.
We are developing products for radiation proctitis (RP), inflammatory bowel disease (IBD), wound healing in the field of cosmetic surgery, and bone and heart muscle regeneration.
Based on the DDS technology to make the required drug act at the required site for the required length of time, we are promoting the delivery of nucleic acid drugs for cancer and malignant pleural mesothelioma.
